Elite Penny Stocks To Watch In October 2026

With US Treasury yields at a 25 year high, investors are feeling the pressure of higher borrowing costs and more cautious risk appetite. That is exactly when solid, under the radar small companies can matter most. This group of low priced stocks combines stronger balance sheets, limited dilution and meaningful insider skin in the game. In this article, three of the best screened ideas are highlighted for closer inspection.

The three stocks covered below are just a sample, with the full screen surfacing 6 more elite penny companies with equally compelling stories that are not included here. To identify and analyze the highest conviction opportunities from the full universe, head straight into the Elite Penny Stocks screener.

Nuvation Bio (NUVB)

Nuvation Bio is a pure play oncology developer centred on IBTROZI and safusidenib. This profile fits the Elite Penny Stocks focus on targeted growth backed by late stage assets rather than side projects or legacy businesses.

Nuvation Bio Inc. develops targeted cancer therapies, led by IBTROZI for ROS1+ lung cancer and safusidenib for IDH1‑mutant astrocytoma. The group generates about US$169.9 million from oncology development activities and carries a market value of roughly US$2.0b.

"IBTROZI is rapidly emerging as the preferred therapy in ROS1 positive non small cell lung cancer, with best in class durability, strong brain penetration and growing first line use."

What happens if a single assumption about how long patients stay on treatment shifts in either direction?

That treatment duration question sits right at the heart of Nuvation Bio’s upside story, and the full narrative for Nuvation Bio explains how this could accelerate or stall value creation.

CBAK Energy Technology (CBAT)

CBAK Energy Technology builds lithium ion and sodium ion batteries for electric vehicles and energy storage, which is exactly the kind of clean energy hardware the Elite Penny Stocks theme targets. The CBAK unit generates about US$123 million and Hitrans about US$107 million in revenue, while the stock’s market value sits near US$118 million.

CBAK Energy Technology gives you direct exposure to EV and grid battery demand, with forecast revenue growth of about 38.1% a year and a P/S near 0.5x that screens as inexpensive for this niche. The real story turns on what happens if one unseen pressure on future profitability shifts direction.

That hidden profitability pressure is exactly what the analysis report for CBAK Energy Technology unpacks so you can see where CBAK Energy Technology could surprise next.

Guerrilla RF (GUER)

Guerrilla RF is a fabless semiconductor specialist focused on radio frequency chips and front end modules for wireless infrastructure and automotive connectivity, generating about US$27 million from high performance MMIC products, with a market value near US$44 million.

Guerrilla RF aligns with the Elite Penny Stocks theme through its RF MMIC focus, combining forecast revenue expansion with a P/S near 1.6x while peers trade closer to 3.4x. The key factor is how quickly RF demand translates into sustainable margins and cash flow.

That margin question is exactly what the analysis report for Guerrilla RF unpacks, so you can see where Guerrilla RF’s growth story could suddenly re rate.

Seeking Alternatives Before Momentum Flies

Fresh opportunities can move from quiet to breakout fast. Use that window before momentum is fully caught and information goes stale. Under the radar for now, act now.

• Spot resilient compounders early and review the curated 31 resilient stocks with low risk scores that focus on durability while prices still look reasonable and attention has not yet flooded in.
• Ride the next wave of automation and scan the hand picked 92 robotics and automation stocks powering factories, warehouses and devices before momentum traders push valuations higher.
• Position ahead of potential AI infrastructure demand and track the quietly building 90 AI infrastructure stocks while these enablers of data and compute are still being priced as afterthoughts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com